Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2023 Aug:118:110595.
doi: 10.1016/j.clinbiochem.2023.110595. Epub 2023 Jun 3.

Prognostic value of secretoneurin in chronic heart failure. Data from the GISSI-Heart Failure trial

Helge Røsjø  1 , Jennifer Meessen  2 , Anett Hellebø Ottesen  1 , Roberto Latini  2 , Torbjørn Omland  3 ; GISSI-HF Investigators
Affiliations
Free article
Multicenter Study

Prognostic value of secretoneurin in chronic heart failure. Data from the GISSI-Heart Failure trial

Helge Røsjø et al. Clin Biochem. 2023 Aug.
Free article

Abstract

Background: Circulating secretoneurin (SN) concentrations have been found to provide prognostic information in patients with acute heart failure. We wanted to assess whether SN would improve prognostication also in patients with chronic heart failure (HF) in a large multicenter trial.

Methods: We measured plasma SN concentrations at randomization (n = 1224) and after 3 months (n = 1103) in patients with chronic, stable HF from the GISSI-HF study. The co-primary endpoints were (1) time to death or (2) admission to hospital for cardiovascular reasons.

Results: Mean age was 67 years and 80% were male. Median (quartile 1-3) SN concentrations were 42.6 (35.0-62.8) pmol/L on randomization and 42.0 (34.5-53.1) pmol/L after 3 months, which are higher than SN concentrations in healthy subjects. Higher SN concentrations at randomization were associated with lower body-mass index (BMI), lower systolic blood pressure, lower estimated glomerular filtration rate (eGFR), higher B-type natriuretic peptide (BNP) concentrations, and diagnosis of chronic obstructive pulmonary disease. During median follow-up of 3.9 years, 344 patients (27.0%) died. After adjusting for age, sex, left ventricular ejection fraction, BMI, functional class, ischemic etiology, heart rate, blood pressure, eGFR, bilirubin, comorbidities, and BNP concentrations, logarithmically transformed SN concentrations on randomization were associated with mortality (HR 2.60 (95% CI 1.01-6.70), p = 0.047). SN concentrations were also associated with admission to hospital for cardiovascular reasons, but the association was attenuated and no longer significant in multivariable analysis.

Conclusion: Plasma SN concentrations provided incremental prognostic information to established risk indices and biomarkers in a large cohort of chronic HF patients.

Keywords: Biomarkers; GISSI-HF; Heart failure; Prognosis; Secretoneurin.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: HR and TO have intellectual property rights for the use of SN as a biomarker in CVD, HR and TO have stocks in CardiNor AS, which holds the patent for SN as a CV biomarker, and HR, AHO, and TO have received consultant fees from CardiNor AS. HR has also received consultant fee from SpinChip Diagnostics.

Publication types

LinkOut - more resources